Serum Institute, Bharat Biotech to Start Late-Stage Trial of Intranasal Covid-19 Vaccine Soon
Little bottles labeled with a “Vaccine COVID-19” sticker and a medical syringe are seen in this illustration taken on April 10,2020 (REUTERS/Dado Ruvic/File Picture)
Harsh Vardhan said the late stage trial normally includes countless individuals, sometimes 30,000 to 40,000 Of the vaccines currently in Stage 3 trials, all are administered by injection, according to the World Health Company (WHO).
- Reuters NEW DELHI
- Last Updated: October 18, 2020, 21: 10 IST
- FOLLOW US ON:
Serum Institute of India and Bharat Biotech are expected to pursue late phase medical trials of intranasal Covid-19 vaccines in the coming months once they get regulatory approval, Union health minister Harsh Vardhan said on Sunday.
Harsh Vardhan stated the late phase trial usually includes countless individuals, in some cases 30,000 to 40,000 Of the vaccines presently in Stage 3 trials, all are administered by injection, according to the World Health Organization (WHO).
On Saturday, India’s Dr Reddy’s Laboratories Ltd and the Russian Direct Mutual Fund (RDIF) stated they have gotten renewed approval to conduct late-stage scientific trials in India of the Russian Covid-19 vaccine.
India’s coronavirus infections rose by another 61,871 over the past 24 hours, data launched on Sunday showed, although the health ministry said it is seeing a pattern of progressively decreasing active cases.
The Indian Council of Medical Research Study (ICMR) stated it will revisit its procedure for COVID-19 treatment after the WHO found a few of the commonly utilized drugs, including remdesivir, had little or no effect on a client’s opportunities of surviving, local media reported earlier on Sunday.
( the heading, this story has not been released by Crucial India News personnel and is released from a syndicated feed.).